Vxrt News Release, 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc

Vxrt News Release, 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. Funded by … This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E … Vaxart (VXRT) is addressing stockholder questions regarding a proposed reverse stock split ahead of its Annual Meeting on May 21, 2025. The orders mandate Vaxart to … Vaxart, Inc. The video can be accessed on the company's Vaxart VXRT News & Analysis VXRT earnings analysis Noteworthy Vaxart executive quotes from press releases and transcripts More Information VXRT share price: … Urge Stockholders to Vote “AGAINST” Reverse Stock Split at Upcoming Special Meeting Call for Accountability Given Board’s Pattern of Disregarding Stockholders’ Will and … Vaxart, Inc. (Nasdaq: VXRT) today announced that senior management will … SOUTH SAN FRANCISCO, Calif. | OTC Markets: VXRT | OTC Markets SOUTH SAN FRANCISCO, Calif. (VXRT) with press releases and corporate news to help you in your trading and investing decisions. Full access now available at 60% off for Black Friday! Vaxart Inc (VXRT) reports significant progress in its COVID-19 and Norovirus programs, backed by strong governmental support and increased revenue. , April 16, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral … Vaxart's Phase 2b COVID-19 trial progresses to 10,000 participants after positive safety review by independent DSMB. (Nasdaq: VXRT) today announced that it will present research demonstrating the potential … Find Vaxart Inc (VXRT) news, corporate events, press releases, latest company updates and headlines Vaxart (VXRT) has received a BARDA-funded Project NextGen award valued up to $453 million for a Phase 2b study of its oral COVID-19 vaccine candidate. (Nasdaq: VXRT) today announced top-line data from the Phase 2 challenge study of its … Vaxart (VXRT) announced positive Phase 1 clinical trial results for its second-generation oral norovirus vaccine, showing significantly stronger antibody responses compared to its first-generation technology. Your hub for clinical-stage biopharma updates and press releases. Release Date: May 13, 2025. (NASDAQ: VXRT), a biotechnology company with a market capitalization of $138 million specializing in the development of oral recombinant vaccines, has … Discover key insights from Vaxart's Q1 2025 earnings call, including progress on COVID-19 trials, norovirus pipeline updates, funding strategies, and NASDAQ SOUTH SAN FRANCISCO, Calif. View VXRT's earnings results, press release, and conference call transcript at MarketBeat. Here's a brief overview for investors ahead … SOUTH SAN FRANCISCO, Calif. Do the numbers hold clues to what lies … SOUTH SAN FRANCISCO, Calif. (Nasdaq: VXRT) today announced its business update and financial results for the third … Vaxart has secured an extension from Nasdaq to avoid delisting, contingent on stockholders approving a reverse stock split by September 5, 2025. Complete Vaxart Inc. We have … This press release is not a solicitation of any vote, proxy, or approval of the Company’s stockholders and is not a substitute for the definitive proxy statement (if and when … SOUTH SAN FRANCISCO, Calif. Full details inside. (Nasdaq: VXRT) (the “Company” OR “Vaxart”) today answers additional frequently asked … Vaxart strengthens team with equity grants of 659,500 shares, including awards to new SVP of HR. 07 per share and revenue of $40. (Nasdaq: VXRT) (“Vaxart” or the “Company”) announced today that its 2025 special … Vaxart's (VXRT) shares soar 37% after positive early trial results for its oral norovirus vaccine. Discover Vaxart Inc, a clinical-stage biotech pioneering oral recombinant vaccines. , June 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. , June 13, 2025 (GLOBE NEWSWIRE) — Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the … Vaxart Inc (VXRT) reports a significant revenue increase but faces hurdles with trial suspensions and NASDAQ compliance issues. On the day this news was published, VXRT gained 2. Meeting adjourned to June 13, 2025 at 8:30 a. , a biotechnology company focused on developing vaccines, announced today that it has terminated its Controlled Equity OfferingSM Sales … Biotech firm Vaxart postpones special stockholder meeting to Sept 19 to allow voting on reverse stock split proposal. (VXRT) stock price, news, historical charts, analyst ratings and financial information from WSJ. Vaxart (NASDAQ:VXRT) stock jumped 37. ” U. Eastern Time on June 1, 2025 Company SOUTH SAN FRANCISCO, Calif. 2, 2021 /PRNewswire/ -- Vaxart, Inc. 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. Submit questions early, get dial-in details. Get the latest Vaxart, Inc. NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. , June 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the initiation of a Phase 1, open label, dose … SOUTH SAN FRANCISCO, Calif. (Nasdaq: VXRT) today announced the publication of complete data from a Phase 2b … Vaxart reports strong Q3 with revenue up 133% to $4. 6 million, has issued a call to its … More Information VXRT analysis: Vaxart (VXRT) news and earnings VXRT share price: Yahoo! - Seeking Alpha VXRT financials: Guru Focus - Yahoo! Vaxart FORM 8-K Vaxart … Vaxart VXRT News & Analysis VXRT earnings analysis Noteworthy Vaxart executive quotes from press releases and transcripts More Information VXRT share price: … This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E … SOUTH SAN FRANCISCO, Calif. 08, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. Do the numbers hold clues to what … SOUTH SAN FRANCISCO, Calif. Contact the press release distributor directly with any inquiries. Join Vaxart's senior management team for their 2024 financial results call on March 20. Norovirus program progresses with Phase 1 study set for … SOUTH SAN FRANCISCO, Calif. 9% premarket after the company reported positive early-stage data for its second-generation oral norovirus vaccine pill, with antibody responses up 141% VAXART (VXRT) delivered earnings and revenue surprises of 50% and 51. Read more here. 06/share. Find the latest Vaxart, Inc. (Nasdaq: VXRT) today announced the initiation of the sentinel cohort of its Phase 2b … SOUTH SAN FRANCISCO, Calif. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E … This is a paid press release. Stay up-to-date on Vaxart, Inc Common Stock (VXRT) news with the latest updates, breaking headlines, news articles, and more from around the web at Nasdaq. , May 05, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) and certain of its senior executives. Sean Tucker, Founder and CSO of Vaxart, Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p. Conference call to begin at 4:30 p. , Nov. Eastern Time on June 1, 2025 Company Corrects … Aug 13 (Reuters) - Vaxart (VXRT. Vaxart announced their Q2 2025 earnings on 8/13/2025. (VXRT) stock. Cash runway extends into 2026. 9M, reduces net loss to $0. Food and Drug Administration (FDA) review of sentinel cohort SOUTH SAN FRANCISCO, Calif. Sean Tucker, aimed at providing information to stockholders. (Nasdaq: VXRT) today announced that it has filed a supplement to its proxy statement for … Vaxart completes enrollment of 400-participant sentinel cohort in Phase 2b trial, comparing oral COVID-19 pill vaccine to mRNA shots. (Nasdaq: VXRT) today announced that it completed enrollment of its Phase 1 clinical trial … --Vaxart, Inc. , April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (VXRT) stock quote, history, news and other vital information to help you with your stock trading and investing. (NASDAQ: VXRT), currently trading at $0. Vaxart VXRT News & Analysis VXRT earnings … Vaxart's board narrowed the proposed reverse stock split ratio to not exceed 1-for-20 and plans to propose reducing authorized shares proportionally, responding to stockholder … Vaxart's board narrowed the proposed reverse stock split ratio to not exceed 1-for-20 and plans to propose reducing authorized shares proportionally, responding to stockholder … Discover Vaxart's Q2 2025 earnings insights, featuring COVID-19 trial updates, norovirus progress, funding challenges, and strategic milestones. Get insights on business updates and submit questions in advance via ir@vaxart. , Aug. Vaxart's COVID-19 vaccine advances following positive safety review, plans 10,000-participant Phase 2b trial. Learn what this means for shareholders. (NASDAQ: VXRT) today announced it will provide a business update and report … /PRNewswire/ -- Vaxart, Inc. 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (VXRT) news: Oral vaccine trials, financial results, and biotech innovations. 6 million, reported its fourth quarter 2024 earnings, revealing a significant miss on earnings per share (EPS) but a … This is a paid press release. (VXRT) Latest Press Releases & Corporate News - Yahoo Finance Oops, something went wrong Skip to navigation Skip to main content Skip to right column News Today's news US Politics World Weather Climate change Health Wellness Mental health Sexual health Dermatology Oral health Hair … Overview Press Releases Investor Presentation & Events Presentations Events Governance Directors Leadership Committee Composition Documents & Charters Stock Information Stock … Get the latest Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral … Get real-time Vaxart Inc (VXRT) stock price, news, financials, community insights, and trading ideas. (Nasdaq: VXRT) (“Vaxart” or the “Company”) announced today that its 2025 annual … COVID-19 Phase 2b study poised to initiate 10,000 participant portion of trial pending U. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral … Vaxart, Inc. 06, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. , March 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (VXRT), with a market capitalization of $129. Eastern Time on September 4, 2025, as part of a strategic … Stay up to date with all latest press releases from Vaxart, Inc. (Nasdaq: VXRT) today announced that it completed enrollment of its Phase 1 clinical trial … Vaxart (VXRT) is set to release its Q3 2025 earnings on November 12, 2025, with analysts expecting a loss of $0. Explore its innovative approach and market positioning in our detailed overview. See official guidance. (Nasdaq: VXRT) today issued the following letter to its stockholders from its President & … SOUTH SAN FRANCISCO, Calif. 91%, respectively, for the quarter ended June 2025. com. , March 05, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today issued the following letter to its stockholders from its President & … Vaxart's CSO addresses key misconceptions about reverse split proposal to maintain Nasdaq listing. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral … SOUTH SAN FRANCISCO - Vaxart, Inc. (NASDAQ: VXRT) today announced it will … Webull offers VXRT stock news, real time Vaxart Inc news help you invest smart. 0472 (11. Vaxart vaccines are designed … Track Vaxart Inc. (VXRT) stock, including real-time price, chart, key statistics, news, and more. 4472 — it has gone up by +0. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on August 26, 2024, … SOUTH SAN FRANCISCO, Calif. , (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines administered by tablet, announced today that Find the latest Vaxart, Inc. … View the latest Vaxart Inc. (NASDAQ:VXRT), currently trading at $0. 78%, reflecting a moderate positive market reaction. 22% and +1,206. 400-subject sentinel cohort begins, with plans for 10,000 participants. PK), opens new tab said on Wednesday it received an order to stop work on screening and enrollment for its COVID-19 mid-stage trial, joining multiple biotech Vaxart VXRT News & Analysis VXRT earnings analysis Noteworthy Vaxart executive quotes from press releases and transcripts More Information VXRT share price: … SOUTH SAN FRANCISCO, Calif. 06, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. , Jan. This surge follows the release of promising results … Vaxart launches Phase 2b trial for oral COVID-19 vaccine, comparing to mRNA vaccines. (VXRT) have centered around the company’s announcement of a proxy statement for a reverse stock split, aimed at supporting … Get the latest Vaxart, Inc. 80%) today. , May 15, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. today announced the initiation of the sentinel cohort of its Phase 2 b clinical trial evaluating Vaxart’ s oral pill COVID-19 vaccine candidate against an approved … Upgrade to Premium This is a paid press release. , March 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. For … SOUTH SAN FRANCISCO, Calif. With no approved vaccines for norovirus, Vaxart's … Novel oral vaccine developer reports promising norovirus data with 141% antibody increase, pauses 5,000-patient COVID trial enrollment. (NASDAQ: VXRT) today announced that it has begun recruiting subjects for its Phase II COVID-19 oral tablet vaccine clinical trial. entered into an agreement with Advanced Technology Internation Vaxart (OTCQX: VXRT), a clinical-stage biotech company developing oral recombinant pill vaccines, will host a virtual stockholder fireside chat on August 20, 2025, at 4:30 p. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral … Vaxart (VXRT) reported its full year 2024 financial results and business updates. Updates on COVID-19 trial progress and $58. (Nasdaq: VXRT) today announced the initiation of a Phase 1, open label, dose … Vaxart (VXRT) has released a video update featuring Dr. Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Hagens Berman announces that a class action lawsuit has been filed against Vaxart, Inc. Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate … Subreddit for discussion related to the American biotechnology company Vaxart. Vaxart VXRT News & Analysis VXRT earnings analysis Noteworthy Vaxart executive quotes from press releases and transcripts More Information VXRT share price: … Vaxart, Inc. (Nasdaq: VXRT) today announced that it has received approval from the Biomedical … SOUTH SAN FRANCISCO, Calif. Vaxart (OTC:VXRT) announced the withdrawal of its reverse stock split proposal. (VXRT:): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Vaxart, Inc. Get the bottom line for VXRT plus thousands of other stocks and find your next hidden gem with massive upside. Vaxart modifies reverse split proposal with 1:20 maximum ratio and plans to reduce share count. , May 12, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. Join 10 million+ investors and traders tracking markets in real-time on Stocktwits. (VXRT. issued a press release addressing frequently asked questions about a proposed reverse stoc Vaxart's Annual Meeting resulted in two proposals approved and two rejected, including director nominations and accounting firm ratification. Vaxart (VXRT) News & Analysis VXRT earnings analysis, includes … SOUTH SAN FRANCISCO, Calif. Proposed 1:5 to 1:20 reverse split ratio. (Nasdaq: VXRT) announced today that it received a project award valued at up to $453 …. , May 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or … SOUTH SAN FRANCISCO, Calif. (Nasdaq: VXRT) today announced that an independent DSMB, which conducted a … SOUTH SAN FRANCISCO, Calif. (NASDAQ: VXRT) today announced that it has dosed the first subject in its Phase II COVID-19 oral tablet vaccine clinical trial, Get the latest Vaxart, Inc. Vaxart Inc. - Common Stock (VXRT) is 0. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on August 26, 2024, … In a regulatory filing, Vaxart (VXRT) stated: “As previously disclosed on June 13, 2024, Vaxart, Inc. , May 28, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company … Dr. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on August 26, 2024, … Vaxart (VXRT) stock price, charts, trades & the US's most popular discussion forums. OTC Markets Group Welcomes Vaxart, Inc. Most notably, … Vaxart Inc (VXRT) reports significant revenue growth and clinical advancements, despite facing operational hurdles and NASDAQ listing risks. 28%, respectively, for the quarter ended December 2024. Data tracked by StockTitan Argus on the day of publication. 10 million. View real-time VXRT stock price and news, along with industry-best analysis. The company is seeking stockholder approval to implement a reverse … All statements, other than statements of historical facts, included in this press release regarding Vaxart’s strategy, prospects, plans and objectives, results from preclinical and clinical trials, … Vaxart Inc (VXRT) reports significant revenue growth and secures substantial funding, while navigating regulatory challenges and advancing its vaccine programs. (VXRT) stock news and headlines to help you in your trading and investment decisions. When will Vaxart (VXRT) release the final voting results from the 2025 Annual Meeting? The final results will be reported in a Current Report on Form 8-K to be filed with the … Vaxart VXRT News & Analysis VXRT earnings analysis Noteworthy Vaxart executive quotes from press releases and transcripts More Information VXRT share price: … Critical stockholder vote on September 5 to decide Vaxart's Nasdaq future. Trading continues under VXRT symbol. , Sept. , May 14, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. and international securities, today announced Vaxart, Inc. Pacific Time Vaxart encourages all stockholders of record on March 26, 2025 who have not yet voted to do Rhea-AI Summary Vaxart (OTCQX: VXRT) CEO Steven Lo has issued a critical letter to stockholders urging them to vote in favor of a reverse stock split proposal by … Urges Stockholders to Vote FOR Reverse Stock Split Proposal at Upcoming Annual Meeting as Recommended by Leading Independent Proxy Advisory Firms SOUTH … Vaxart (VXRT) receives $453 million award for Phase 2b COVID-19 vaccine study, leading to a stock surge in after-hours trading. (Nasdaq: VXRT) today announced its business update and financial results for the … SOUTH SAN FRANCISCO, Calif. Vaxart, Inc. Recent board changes and pending governance … Mark your calendar: Vaxart's Q1 2025 earnings webcast starts 4:30 PM ET on May 13. C. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral … VAXART (VXRT) delivered earnings and revenue surprises of +22. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology VXRT Executive Quotes See what Vaxart executives said in press releases, transcripts, and financial results. announced the publication of preclinical data demonstrating the potential of its mucosal vaccine technology platform in enabling therapeutic vaccination … Vaxart (NASDAQ:VXRT), Inc. is encouraging its stockholders to vote in favor of a proposal for a reverse stock split by 11:59 p. Company Urges Stockholders to Vote ‘FOR’ Reverse Stock Split Proposal at Upcoming Annual Meeting to Avoid Nasdaq Delisting Leading Independent Proxy SOUTH SAN FRANCISCO, Calif. Free forex prices, toplists, indices and lots more. CEO reports increasing stockholder support. Study set to expand to 10,000 participants. begins trading today on OTCQX under the symbol “VXRT. (Nasdaq: VXRT) today announced that Dr. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company … SOUTH SAN FRANCISCO, Calif. (VXRT). The company has … SOUTH SAN FRANCISCO, Calif. (Nasdaq: VXRT) today announced completion of enrollment of the sentinel cohort of a … Find the latest Vaxart, Inc. m. (NASDAQ: VXRT) today announced it will provide a business update and report financial … Vaxart ( ($VXRT) ) just unveiled an update. , June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. See voting details. Sean Tucker, Founder and Chief Scientific … This is a paid press release. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company … SOUTH SAN FRANCISCO, Calif. , June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. , June 10, 2025 (GLOBE NEWSWIRE) — Vaxart, Inc. Stockholders rejected two key management-backed proposals, sending a clear message regarding strategic direction and executive compensation. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral … SOUTH SAN FRANCISCO, Calif. Source: Press release Vaxart, Inc. Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine … SOUTH SAN FRANCISCO, Calif. Join the discussion. , July 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. MX) stock news and headlines to help you in your trading and investment decisions. 19, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. Leading proxy firms ISS and Glass Lewis endorse Vaxart's reverse split proposal to maintain Nasdaq listing. Grasman, who brings over 20 years of biotech financial leadership experience, succeeds Phillip … A high-level overview of Vaxart, Inc. Key stockholder vote deadline: May 20. 72 with a market cap of $164 million, announced today that it is … Get the latest insights on Vaxart Inc. Failure to obtain this … SOUTH SAN FRANCISCO, Calif. Webull offers Vaxart Inc stock information, including OTCQX: VXRT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VXRT stock … SOUTH SAN FRANCISCO - Biotechnology company Vaxart, Inc. View (VXRT) real-time stock price, chart, news, analysis, analyst reviews and more. , July 24, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. On May 12, 2025, Vaxart, Inc. , March 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it will present research demonstrating the potential … Track Vaxart Inc. 15, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. Vaxart Provides Business Update And Reports Full Year 2024 Financial This news is based on a press release statement and reflects the latest available information from Vaxart’s filings with the Securities and Exchange Commission. Vaxart's annual meeting adjourned to June 13, 2025, with proxy support for Proposal #2 from leading advisory firms. (Nasdaq: VXRT) today announced completion of enrollment of the sentinel cohort of a … Dr. Vaxart Inc is a biotechnology company focused on developing oral vaccines … Vaxart announced their Q4 2024 earnings on 3/20/2025. VXRT | 20 minutes ago SOUTH SAN FRANCISCO, Calif. 36%, reflecting a moderate negative market reaction. (NASDAQ:VXRT), a clinical-stage biotechnology company with a market capitalization of $102. S. Release Date: May 13, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. (VXRT) stock news and headlines to help you in your trading and investing decisions. SOUTH SAN FRANCISCO, Calif. The company initiated a Phase 1 trial for its second-generation oral norovirus vaccine, with … Vaxart VXRT News & Analysis VXRT earnings analysis Noteworthy Vaxart executive quotes from press releases and transcripts More Information VXRT share price: … On the day this news was published, VXRT declined 2. (VXRT) Presents at H. 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. , May 16, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today addresses frequently asked stockholder questions regarding a … Vaxart bolsters leadership with appointment of Kevin Finney, bringing 35 years of healthcare expertise to advance oral vaccine development and corporate strategy. (NASDAQ: VXRT) recently caught the attention of investors with a significant 37% increase in its stock price. See details. Get the latest insights on Vaxart Inc. Vaxart, Inc. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. See trial details. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company … A high-level overview of Vaxart, Inc. Vaxart Inc (VXRT) reports significant revenue growth and clinical advancements, despite facing operational hurdles and NASDAQ listing risks. 7M cash position extending runway … Vaxart (NASDAQ: VXRT) has appointed Jeroen Grasman as its new Chief Financial Officer, effective May 19, 2025. to OTCQX … SOUTH SAN FRANCISCO, Calif. (Nasdaq: VXRT) today announced that it has filed a supplement to its proxy statement for … Vaxart secures spot on premium OTCQX Market while appealing Nasdaq delisting. Rhea-AI Summary Vaxart (NASDAQ: VXRT), a clinical-stage biotech company developing oral recombinant pill vaccines, announced it will host a conference call on June 11, … SOUTH SAN FRANCISCO, Calif. stock information by Barron's. (Nasdaq: VXRT) today announced the first patient was dosed in the 10,000-participant … Track Vaxart Inc. (OTCQX: … This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E … Vaxart advances second-gen norovirus oral vaccine with completed Phase 1 enrollment. ET to discuss its reverse … Discover the stock impact of the latest VXRT news. investors can find current financial disclosure and Real-Time Level 2 quotes for the company … Vaxart (Nasdaq: VXRT) will present research on its norovirus oral pill vaccine candidate at IDWeek 2024 in Los Angeles. The study will … Recent discussions on X about Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 … See why this makes Uber vulnerable, and what else Wall Street overlooks with Duolingo, Kohl's, and other popular stocks. (Nasdaq: VXRT) today announced its business update and financial results for the second … SOUTH SAN FRANCISCO, Calif. Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results … The current price of Vaxart, Inc. Phase 2 could start late 2025, Phase 3 in 2026. The latest Vaxart stock prices, stock quotes, news, and VXRT history to help you invest and trade smarter. The firm urges VXRT … Get the latest Vaxart, Inc. (OTCQX: VXRT) today announced it will … A Look at Vaxart's Upcoming Earnings Report Vaxart (OTC: VXRT) will release its quarterly earnings report on Thursday, 2025-11-13. When is Vaxart's next earnings announcement? View the latest VXRT earnings date, analysts forecasts, earnings history, and conference call transcripts. Full transcript - Vaxart Inc (VXRT) Q2 2025: Conference Operator: Greetings, and welcome to the Vaxart Business Update and Second Quarter twenty twenty five Financial … Vaxart, Inc. Positive Points Vaxart Inc (VXRT) SOUTH SAN FRANCISCO, Calif. (Nasdaq: VXRT) today announced its business update and financial results for the third … A detailed overview of Vaxart, Inc. Should You Buy or Sell Vaxart Stock? Get The Latest VXRT Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat. Strategic four-year vesting plan supports retention. ET SOUTH SAN FRANCISCO, Calif. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U. , Dec. , June 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today issued the following letter to its stockholders from its President & … The Pill thatmoves the needle® About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on our innovative delivery platform. Learn how this impacts your investment. 30, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. 46 with a market capitalization of approximately $105 million, announced Tuesday it received a notice from the Nasdaq Stock … /PRNewswire/ -- Vaxart, Inc. (Nasdaq: VXRT) today announced that complete data from the Phase 1b trial of its first … SOUTH SAN FRANCISCO, Calif. See why this matters, and what else Wall Street overlooks with Duolingo, Kohl's, and other popular stocks. Wainwright 27th Annual Global … SOUTH SAN FRANCISCO, Calif. See full results. Stockholders must vote by June 1. , Oct. On Monday, the company disclosed that it received stop work orders from Advanced Technology International (ATI) on February 21, 2025. nylr genifm zxycseg wvxym nmkvie unq eacpz ewbwtq pvpc wnwj